Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.
Betsy O'Donnell, MD, medical oncologist, Multiple Myeloma Disease Center, director of Lifestyle Medicine, Massachusetts General Hospital, discusses the promise of novel targets in multiple myeloma.
Significant progress in targeting B-cell maturation antigen (BCMA) has been made in multiple myeloma, O’Donnell says. Moreover, BCMA-directed therapies, such as CAR T-cell therapies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates, are FDA approved or under investigation in this setting, O’Donnell says.
However, the field is evaluating novel targets beyond BCMA for patients who become refractory to BCMA-directed treatments, O’Donnell says. For example, talquetamab, which targets GPRC5D, and cevostamab (BFCR4350A), which targets FcRH5, are under investigation, concludes O’Donnell.